Serina King

723 total citations
18 papers, 527 citations indexed

About

Serina King is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Serina King has authored 18 papers receiving a total of 527 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Serina King's work include Prostate Cancer Treatment and Research (11 papers), Prostate Cancer Diagnosis and Treatment (4 papers) and Histone Deacetylase Inhibitors Research (4 papers). Serina King is often cited by papers focused on Prostate Cancer Treatment and Research (11 papers), Prostate Cancer Diagnosis and Treatment (4 papers) and Histone Deacetylase Inhibitors Research (4 papers). Serina King collaborates with scholars based in United States, Netherlands and Chile. Serina King's co-authors include Michael A. Carducci, Emmanuel S. Antonarakis, Michelle A. Rudek, Rana Sullivan, Роберто Пили, Ming Zhao, Janet Mendonca, Sushant K. Kachhap, David C. Smith and Elisabeth I. Heath and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Urology and British Journal of Cancer.

In The Last Decade

Serina King

17 papers receiving 513 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Serina King United States	8	342	129	114	77	41	18	527
Andrew DeCastro United States	11	249 0.7×	156 1.2×	27 0.2×	97 1.3×	31 0.8×	15	472
Shankar Jagadeesh United States	12	353 1.0×	56 0.4×	60 0.5×	54 0.7×	17 0.4×	18	537
Nianping Chen China	12	284 0.8×	79 0.6×	44 0.4×	96 1.2×	11 0.3×	18	457
W. K. Hong United States	6	210 0.6×	140 1.1×	60 0.5×	75 1.0×	16 0.4×	9	465
Xiaodan Sun China	14	304 0.9×	113 0.9×	62 0.5×	121 1.6×	10 0.2×	39	556
Deepak Poudyal United States	14	436 1.3×	106 0.8×	27 0.2×	163 2.1×	26 0.6×	17	770
Nader S. Shenouda United States	5	210 0.6×	84 0.7×	49 0.4×	57 0.7×	19 0.5×	5	391
Jiao Li China	16	392 1.1×	107 0.8×	68 0.6×	132 1.7×	9 0.2×	31	686
Claudia Burz Romania	14	295 0.9×	233 1.8×	103 0.9×	145 1.9×	18 0.4×	42	678
Tamene Melkamu United States	11	269 0.8×	60 0.5×	43 0.4×	124 1.6×	14 0.3×	16	483

Countries citing papers authored by Serina King

Since Specialization

Citations

This map shows the geographic impact of Serina King's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Serina King with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Serina King more than expected).

Fields of papers citing papers by Serina King

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Serina King. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Serina King. The network helps show where Serina King may publish in the future.

Co-authorship network of co-authors of Serina King

This figure shows the co-authorship network connecting the top 25 collaborators of Serina King. A scholar is included among the top collaborators of Serina King based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Serina King. Serina King is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Marshall, Catherine H., Benjamin A. Teply, Su Jin Lim, et al.. (2023). Phase 2 study of olaparib (without ADT) in men with biochemically recurrent prostate cancer (BCR) after prostatectomy.. Journal of Clinical Oncology. 41(16_suppl). 5087–5087. 4 indexed citations

Markowski, Mark C., Cora N. Sternberg, Hao Wang, et al.. (2023). TRIUMPH: Phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline DNA repair gene mutations.. Journal of Clinical Oncology. 41(6_suppl). 190–190. 6 indexed citations

Marshall, Catherine H., Jong Chul Park, Theodore L. DeWeese, et al.. (2020). Randomized phase II study of sipuleucel-T (SipT) with or without radium-223 (Ra223) in men with asymptomatic bone-metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 38(6_suppl). 130–130. 7 indexed citations

Antonarakis, Emmanuel S., Hao Wang, Benjamin A. Teply, et al.. (2019). Interim results from a phase 2 study of olaparib (without ADT) in men with biochemically-recurrent prostate cancer after prostatectomy, with integrated biomarker analysis.. Journal of Clinical Oncology. 37(15_suppl). 5045–5045. 15 indexed citations

Teply, Benjamin A., Hao Wang, Rana Sullivan, et al.. (2018). Phase II study of olaparib (without ADT) in men with high-risk biochemically-recurrent prostate cancer following prostatectomy, with integrated biomarker analysis.. Journal of Clinical Oncology. 36(6_suppl). TPS386–TPS386. 1 indexed citations

Пили, Роберто, Glenn Liu, Sreenivasulu Chintala, et al.. (2017). Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial. British Journal of Cancer. 116(7). 874–883. 75 indexed citations

Paller, Channing J., Elisabeth I. Heath, Mary‐Ellen Taplin, et al.. (2017). A phase II study of muscadine grape skin extract in men with biochemically recurrent prostate cancer.. Journal of Clinical Oncology. 35(6_suppl). 248–248. 2 indexed citations

Park, Jong Chul, Oliver Sartor, Rana Sullivan, Serina King, & Emmanuel S. Antonarakis. (2015). Randomized phase-2 study of sipuleucel-T with or without radium-223 in men with asymptomatic/minimally symptomatic bone-metastatic castrate-resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 33(15_suppl). TPS5076–TPS5076. 7 indexed citations

Paller, Channing J., Michelle A. Rudek, Xian Zhou, et al.. (2015). A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination. The Prostate. 75(14). 1518–1525. 102 indexed citations

10.

Paller, Channing J., Michelle A. Rudek, Emmanuel S. Antonarakis, et al.. (2014). A phase I trial of muscadine grape skin in men with biochemically recurrent prostate cancer.. Journal of Clinical Oncology. 32(4_suppl). 263–263.

11.

Antonarakis, Emmanuel S., Elisabeth I. Heath, David C. Smith, et al.. (2013). Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration-Resistant Prostate Cancer. The Oncologist. 18(2). 163–173. 135 indexed citations

12.

Freedland, Stephen J., Michael Carducci, Nils Kroeger, et al.. (2013). A Double-Blind, Randomized, Neoadjuvant Study of the Tissue Effects of POMx Pills in Men with Prostate Cancer Before Radical Prostatectomy. Cancer Prevention Research. 6(10). 1120–1127. 59 indexed citations

13.

Schweizer, Michael, Aditya Bardia, Amanda L. Blackford, et al.. (2013). A prostate cancer clinical trials consortium trial of disulfiram (D) in men with nonmetastatic recurrent prostate cancer (PCa).. Journal of Clinical Oncology. 31(6_suppl). 219–219. 3 indexed citations

14.

Freedland, Stephen J., Michael A. Carducci, Nils Kroeger, et al.. (2012). 174 A PHASE II RANDOMIZED CONTROLLED TRIAL OF POMX VS. PLACEBO PRIOR TO RADICAL PROSTATECTOMY. The Journal of Urology. 187(4S). 1 indexed citations

15.

Antonarakis, Emmanuel S., Elisabeth I. Heath, David C. Smith, et al.. (2011). A noncomparative randomized phase II study of two dose levels of itraconazole in men with metastatic castration-resistant prostate cancer (mCRPC): A DOD/PCCTC trial.. Journal of Clinical Oncology. 29(15_suppl). 4532–4532. 4 indexed citations

16.

Пили, Роберто, Mario A. Eisenberger, Avery Spitz, et al.. (2010). A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone. Cancer Chemotherapy and Pharmacology. 67(2). 431–438. 1 indexed citations

17.

Siu, Lillian L., Роберто Пили, Ignacio Durán, et al.. (2008). Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 26(12). 1940–1947. 104 indexed citations

18.

Siu, Lillian L., et al.. (2006). 300 POSTER Phase I study of an oral isotype-selective histone deacetylase (HDAC) inhibitor in patients (pts) with advanced solid tumors. European Journal of Cancer Supplements. 4(12). 94–95. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact